Pulmonary hypertension in infants with bronchopulmonary dysplasia

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

An increase in the number of preterm infants and a decrease in the gestational age at birth have resulted in an increase in the number of patients with significant bronchopulmonary dysplasia (BPD) and secondary pulmonary hypertension (PH). PH contributes significantly to the high morbidity and mortality in the BPD patients. Therefore, regular monitoring for PH by using echocardiography and B-type natriuretic peptide (BNP) or N-terminal-proBNP must be conducted in the BPD patients with greater than moderate degree to prevent PH and to ensure early treatment if PH is present. In the BPD patients with significant PH, multi-modality treatment, including treatment for correcting an underlying disease, oxygen supply, use of diverse selective pulmonary vasodilators (inhaled nitric oxide, inhaled prostacyclins, sildenafil, and endothelinreceptor antagonist) and other methods, is mandatory.

Original languageEnglish
Pages (from-to)688-693
Number of pages6
JournalKorean Journal of Pediatrics
Volume53
Issue number6
DOIs
StatePublished - 1 Jan 2010

Fingerprint

Bronchopulmonary Dysplasia
Pulmonary Hypertension
Prostaglandins I
Brain Natriuretic Peptide
Vasodilator Agents
Premature Infants
Gestational Age
Echocardiography
Nitric Oxide
Therapeutics
Parturition
Oxygen
Morbidity
Lung
Mortality

Keywords

  • Brain natriuretic peptide
  • Bronchopulmonary dysplasia
  • Echocardiography
  • Pulmonary hypertension
  • Vasodilator

Cite this

@article{b4c1d2e6d0b64097a256972acead7ce9,
title = "Pulmonary hypertension in infants with bronchopulmonary dysplasia",
abstract = "An increase in the number of preterm infants and a decrease in the gestational age at birth have resulted in an increase in the number of patients with significant bronchopulmonary dysplasia (BPD) and secondary pulmonary hypertension (PH). PH contributes significantly to the high morbidity and mortality in the BPD patients. Therefore, regular monitoring for PH by using echocardiography and B-type natriuretic peptide (BNP) or N-terminal-proBNP must be conducted in the BPD patients with greater than moderate degree to prevent PH and to ensure early treatment if PH is present. In the BPD patients with significant PH, multi-modality treatment, including treatment for correcting an underlying disease, oxygen supply, use of diverse selective pulmonary vasodilators (inhaled nitric oxide, inhaled prostacyclins, sildenafil, and endothelinreceptor antagonist) and other methods, is mandatory.",
keywords = "Brain natriuretic peptide, Bronchopulmonary dysplasia, Echocardiography, Pulmonary hypertension, Vasodilator",
author = "Kim, {Gi Beom}",
year = "2010",
month = "1",
day = "1",
doi = "10.3345/kjp.2010.53.6.688",
language = "English",
volume = "53",
pages = "688--693",
journal = "Korean Journal of Pediatrics",
issn = "1738-1061",
publisher = "Korean Pediatric Society",
number = "6",

}

Pulmonary hypertension in infants with bronchopulmonary dysplasia. / Kim, Gi Beom.

In: Korean Journal of Pediatrics, Vol. 53, No. 6, 01.01.2010, p. 688-693.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pulmonary hypertension in infants with bronchopulmonary dysplasia

AU - Kim, Gi Beom

PY - 2010/1/1

Y1 - 2010/1/1

N2 - An increase in the number of preterm infants and a decrease in the gestational age at birth have resulted in an increase in the number of patients with significant bronchopulmonary dysplasia (BPD) and secondary pulmonary hypertension (PH). PH contributes significantly to the high morbidity and mortality in the BPD patients. Therefore, regular monitoring for PH by using echocardiography and B-type natriuretic peptide (BNP) or N-terminal-proBNP must be conducted in the BPD patients with greater than moderate degree to prevent PH and to ensure early treatment if PH is present. In the BPD patients with significant PH, multi-modality treatment, including treatment for correcting an underlying disease, oxygen supply, use of diverse selective pulmonary vasodilators (inhaled nitric oxide, inhaled prostacyclins, sildenafil, and endothelinreceptor antagonist) and other methods, is mandatory.

AB - An increase in the number of preterm infants and a decrease in the gestational age at birth have resulted in an increase in the number of patients with significant bronchopulmonary dysplasia (BPD) and secondary pulmonary hypertension (PH). PH contributes significantly to the high morbidity and mortality in the BPD patients. Therefore, regular monitoring for PH by using echocardiography and B-type natriuretic peptide (BNP) or N-terminal-proBNP must be conducted in the BPD patients with greater than moderate degree to prevent PH and to ensure early treatment if PH is present. In the BPD patients with significant PH, multi-modality treatment, including treatment for correcting an underlying disease, oxygen supply, use of diverse selective pulmonary vasodilators (inhaled nitric oxide, inhaled prostacyclins, sildenafil, and endothelinreceptor antagonist) and other methods, is mandatory.

KW - Brain natriuretic peptide

KW - Bronchopulmonary dysplasia

KW - Echocardiography

KW - Pulmonary hypertension

KW - Vasodilator

UR - http://www.scopus.com/inward/record.url?scp=79951686318&partnerID=8YFLogxK

U2 - 10.3345/kjp.2010.53.6.688

DO - 10.3345/kjp.2010.53.6.688

M3 - Article

C2 - 21189939

AN - SCOPUS:79951686318

VL - 53

SP - 688

EP - 693

JO - Korean Journal of Pediatrics

JF - Korean Journal of Pediatrics

SN - 1738-1061

IS - 6

ER -